Fortress Biotech, Inc. (FBIO) Return on equity 2016–2025
Fortress Biotech, Inc. (FBIO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
13.7%FY2025 · since FY2016: -143.1% → 13.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 13.7% | +216.0 pp |
| FY2024 | -202.3% | +66.7 pp |
| FY2023 | -269.0% | -61.5 pp |
| FY2022 | -207.5% | -148.0 pp |
| FY2021 | -59.5% | -13.2 pp |
| FY2020 | -46.4% | +106.1 pp |
| FY2019 | -152.4% | +4391.1 pp |
| FY2018 | -4543.6% | -4416.4 pp |
| FY2017 | -127.2% | +15.9 pp |
| FY2016 | -143.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More FBIO financial trends
FBIO RevenueFBIO Net incomeFBIO Net marginFBIO Gross profitFBIO Gross marginFBIO Operating incomeFBIO Operating marginFBIO Operating cash flowFBIO Free cash flowFBIO Capital expendituresFBIO Stock buybacksFBIO Dividends paidFBIO Total assetsFBIO Total liabilitiesFBIO Shareholders’ equityFBIO overview →